edited by Joseph G. Sinkovics
Viral Therapy of Human Cancers gauges the potential for viruses to act as oncolytic and anti-tumor agents for the treatment of cancers in humans-detailing the cancer-combative properties exhibited by viruses in nature, genetically engineered viruses, and viral oncolysates as evidenced in basic and experimental studies.
Features:
- Lists more than 50 oncolytic adenovirus preparations
- Inspects the rational development of oncolytic viruses through genetic modification of influenza A viruses
- Assesses the engineering of oncolytic viruses acting in tumor cells with eliminated or disabled RB or r53
- Considers genetic engineering enhancement of the oncolytic potency of the measles virus
- Examines possible links between superior survival rates in cancer patients and use of the Newcastle disease virus
- Explores tapping the Newcastle disease virus for management of stage III malignant melanoma
- Regards the immunotherapy of melanoma by way of vaccinia viral lysates
- Includes chapters on measles, influenza, and herpes simplex viruses; parvoviruses; poliovirus recombinants; Newcastle disease viruses and viral oncolysates; and vaccinia viral lysates
Contents
- Progressive Development of the Viral Therapy of Human Cancers: A Personal Narrative Account
- New Biological Therapeutics: Competitors or Collaborators in Viral Therapy for Human Cancers
- Naturally Oncolytic Viruses
- Measles Virus: Improving Natural Oncolytic Properties by Genetic Engineering
- Newcastle Disease Virus: Anti-tumor Immune Memory and Its Activation for Control of Residual Tumor Cells and Improvement of Patient Survival
- Newcastle Disease Virus: Its Oncolytic Properties
- Influenza A Viruses with Deletions in the NS1 Gene: A Rational Approach to Develop Oncolytic Viruses
- Vaccinia Viral Lysates in Immunotherapy of Melanoma
- Genetically Engineered Oncolytic Viruses
- Fusogenic Oncolytic Herpes Simplex Viruses for Therapy of Solid Tumors
- Poliovirus Recombinants Against Malignant Glioma
- Oncolytic Viruses that Depend on Loss of RB
Index